Trials / Terminated
TerminatedNCT01759511
Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Simtuzumab | 200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1) |
Timeline
- Start date
- 2012-10-18
- Primary completion
- 2016-02-19
- Completion
- 2016-02-19
- First posted
- 2013-01-03
- Last updated
- 2017-04-04
- Results posted
- 2017-04-04
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01759511. Inclusion in this directory is not an endorsement.